Fiduciary Trust Co Sells 1,113 Shares of Novo Nordisk A/S (NYSE:NVO)

Fiduciary Trust Co reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 197,566 shares of the company’s stock after selling 1,113 shares during the quarter. Fiduciary Trust Co’s holdings in Novo Nordisk A/S were worth $16,995,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL increased its position in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares during the period. Transce3nd LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $39,000. Finally, Albion Financial Group UT increased its stake in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 4.1 %

Shares of NVO opened at $64.78 on Friday. The business has a 50-day moving average of $69.65 and a 200 day moving average of $86.58. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a market cap of $290.72 billion, a P/E ratio of 19.69, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. BMO Capital Markets reaffirmed a “market perform” rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.